Ghana vaccine approval a ‘critical step’ in combatting malaria
Drug Discovery World
APRIL 13, 2023
The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SIIPL), leveraging Novavax’s adjuvant technology. The vaccine has been approved for use in children aged five to 36 months, the age group at highest risk of death from malaria.
Let's personalize your content